crizotinib acetate

Crizotinib, an orally bioavailable agent, belongs to the class of c-met hepatocyte growth factor receptor (HGFR) tyrosine kinase inhibitors with potential antineoplastic activity.

PF-06463922 acetate is a potent, selective brain-penetrable inhibitor of both anaplastic lymphoma kinase (ALK) and c-ros Oncogene 1 (ROS1) with strong activity against all known ALK and ROS1 mutants identified in patients with crizotinib-resistant disease. PF-06463922 is in clinical trials for the treatment of non–small cell lung cancer (NSCLC).